ANDA Complete Responses Spike In FY 2018, But Why?
Executive Summary
In the first quarter of FY 2018, the agency issued over 800 CRs for generic drug applications, more than half the total it issued in all of FY 2017.
You may also be interested in...
As US FDA Shutdown Continues, What Will Be The Cost Of Not Spending?
Bolus of applications could be filed once government reopens, but employee morale and recruitment efforts could suffer drop-off.
As US FDA Shutdown Continues, What Will Be The Cost Of Not Spending?
Bolus of applications could be filed once government reopens, but employee morale and recruitment efforts could suffer drop-off.
Generic Review At US FDA: Record Month Completes Approval Volume Recovery
With 96 full ANDA approvals and 30 tentative approvals, July was the most productive month since GDUFA launched.